Prs42 Concomitant Asthma Medication Use in Patients Using Omalizumab: Results From Three Large Insurance Claims Databases

Value in Health - United Kingdom
doi 10.1016/j.jval.2011.02.803
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Validity Assessment of Self-Reported Medication Use by Comparing to Pharmacy Insurance Claims

BMJ Open
Medicine
2015English

Level of Asthma Control and Its Relationship With Medication Use in Asthma Patients in Brazil

Jornal Brasileiro de Pneumologia
PulmonaryRespiratory Medicine
2014English

Omalizumab Treatment in Brittle Asthma

Postepy Dermatologii I Alergologii
DermatologyAllergyImmunology
2014English

Omalizumab in Patients With Severe Asthma and Persistent Sputum Eosinophilia

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Reduced Asthma Exacerbations and Asthma-Related Healthcare Resource Use With Omalizumab From the Real-World PROSPERO Study

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Appropriate Selection for Omalizumab Treatment in Patients With Severe Asthma?

European Clinical Respiratory Journal
2017English

Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by Prior Omalizumab Treatment Duration

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

BPM Development for Insurance Claims Using Pega

International Journal of u- and e- Service, Science and Technology
Computer NetworksSoftwareCommunications
2017English

Omalizumab Reduced Inhaled Corticosteroid Use and Exacerbations in Childhood Allergic Asthma

Evidence-Based Medicine
Medicine
2002English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy